David Eugene Maxwell

US Patent:

7899237, Mar 1, 2011

Filed:

Mar 8, 2007

Appl. No.:

11/683548

Inventors:

Dat T. Nguyen - Dallas TX, US
Thao To - Dallas TX, US
David Maxwell - Dallas TX, US
Naweed Anjum - Dallas TX, US

Assignee:

Texas Instruments Incorporated - Dallas TX

International Classification:

G06K 9/00

US Classification:

382141, 382140, 382144, 382145, 382147, 382149, 382151

Abstract:

An embodiment relates generally to a method of testing a mixed signal device. The method includes monitoring multiple parameters of the mixed signal device and scanning the mixed signal device with an optical source. The method also includes forming multiple windows, where each window is assigned to a respective parameter. The method further includes comparing an image from a respective image to a reference image to determine an existence of an anomaly.

US Patent:

20080044348, Feb 21, 2008

Filed:

Jun 29, 2007

Appl. No.:

11/771868

Inventors:

Juri Gelovani - Pearland TX, US
Lucia LeRoux - Houston TX, US
David Schellingerhout - Houston TX, US
David Maxwell - Pearland TX, US
Main Alauddin - Houston TX, US

International Classification:

A61K 49/00
A61K 49/04
A61K 49/14
C12N 1/20
G06F 17/00

US Classification:

424001110, 424009100, 424009300, 424009400, 424009600, 435252700, 707104100, 707E17044

Abstract:

Methods for purifying Tetanus Toxin Fragment C comprising obtaining a supernatant comprising soluble Tetanus Toxin Fragment C and purifying Tetanus Toxin Fragment C under native conditions to obtain a substantially purified Tetanus Toxin Fragment C. Imaging agents comprising a Tetanus Toxin Fragment C and a reporter, and methods thereof. Methods comprising processing confocal microscopy datasets to provide a 360 degree average fluorescence intensity profile from the center of a spheroid towards the outer edge of the spheroid.

US Patent:

20090281115, Nov 12, 2009

Filed:

Jun 29, 2007

Appl. No.:

12/307001

Inventors:

William Bornmann - Missouri City TX, US
David Maxwell - Pearland TX, US
Ashutosh Pal - Houston TX, US
Zhenghong Peng - Missouri City TX, US
Zeev Estrov - Houston TX, US

Assignee:

Board of Regents, The University of Texas System, a Texas University - Austin TX

International Classification:

A61K 31/496
C07D 471/04
A61K 31/437
A61P 35/00
C12N 9/99

US Classification:

51425304, 546119, 514303, 544362, 435184

Abstract:

Compounds and methods useful as inhibitors of c-Kit are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of c-Kit and processes for synthesizing these compounds are also described herein.

US Patent:

20100062465, Mar 11, 2010

Filed:

Apr 20, 2007

Appl. No.:

12/297832

Inventors:

Sabrina M. Ronen - Bellaire TX, US
Juri G. Gelovani - Missouri City TX, US
William G. Bornmann - Missouri City TX, US
Jihai Pang - Pearland TX, US
Ashutosh Pal - Houston TX, US
William P. Tong - Houston TX, US
Ashutosh Paz - Houston TX, US
David S. Maxwell - Pearland TX, US

International Classification:

C12Q 1/34
C07C 271/10
C07F 7/22
C07C 233/01

US Classification:

435 18, 560159, 556 87, 564158

Abstract:

Provided are compositions and methods for intracellular detection of enzyme activity. One example of a composition is a histone deacetylase substrate comprising a compound of the following formula (I): One example of a method is a method for detecting histone deacetylase activity comprising introducing a compound according to formula (1) to a plurality of cells and monitoring the cells with magnetic resonance spectroscopy.

US Patent:

20100144738, Jun 10, 2010

Filed:

Aug 29, 2007

Appl. No.:

12/439491

Inventors:

William Bornmann - Missouri City TX, US
David Maxwell - Pearland TX, US
Yunming Ying - Austin TX, US
Dongmei Han - San Mateo CA, US
Zhenghong Peng - Missouri City TX, US
Varsha Gandhi - Houston TX, US
Christine Stellrecht - Friendswood TX, US

International Classification:

A61K 31/522
C07D 473/00
C07D 487/04
A61K 31/5025
A61P 25/00

US Classification:

514248, 544276, 544236, 51426323

Abstract:

The present invention relates to compounds and methods use as inhibitors of c-Met. Certain compounds of the subject invention have the following structural formula (I). Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention.

US Patent:

20100144743, Jun 10, 2010

Filed:

Sep 4, 2007

Appl. No.:

12/439402

Inventors:

William Bornmann - Missouri City TX, US
David Maxwell - Pearland TX, US
Zhenghong Peng - Missouri City TX, US
Liwei Guo - Birmingham AL, US

Assignee:

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

International Classification:

A61K 31/506
C07D 239/42
C07D 403/10
C07D 471/04
A61K 31/4985
A61P 35/00

US Classification:

514249, 544329, 544328, 544350, 514256

Abstract:

Compositions for inhibiting the catalytic activity of tyrosine kinases comprising compounds represented by Formulas (I), (II), and (III). Methods for treating proliferative diseases comprising administering a therapeutically effective amount of the above compositions.

US Patent:

20100152140, Jun 17, 2010

Filed:

Jan 18, 2008

Appl. No.:

12/529252

Inventors:

Ja Seok Koo - Pearland TX, US
William Bornmann - Missouri City TX, US
David Maxwell - Pearland TX, US

International Classification:

A61K 31/66

US Classification:

514119

Abstract:

In one embodiment, the present invention relates to a method of treating a cancer characterized by overexpression of cyclic adenosine monophosphate response element-binding protein (CREB) or phosphorylated CREB (p-CREB) by administering to a patient suffering from the cancer a pharmaceutically-effective amount of a composition comprising a compound selected from the group consisting of 2-{1-[3-(Amidinothio)propyl]-1H-indol-3-yl}-3-(1-methylindol-3-yl)maleimide, naphthol analogs having the structure (I), wherein Ris selected from the group consisting of —H, —F, —Cl, —Br, and —I; Ris selected from the group consisting of —H, —F, —Cl, —Br, —I, —Calkyl, —Calkenyl, and —Calkynyl; Ris selected from the group consisting of —H and —NO; and Ris selected from the group consisting of —H, —Calkyl, —Calkenyl, —Calkynyl, —OCalkyl, —OCalkenyl, and —OCalkynyl; and salts and esters thereof.

US Patent:

20100292229, Nov 18, 2010

Filed:

Jul 2, 2007

Appl. No.:

12/307088

Inventors:

Nicholas J Donato - Sugar Land TX, US
David Maxwell - Pearland TX, US
Moshe Talpaz - Houston TX, US
William Bornmann - Missouri City TX, US
Zhenghong PENG - Missouri City TX, US
Ashutosh Pal - Houston TX, US
Dongmei Han - Houston TX, US
Shimei Wang - Houston TX, US
Geoffrey Bartholomeusz - Houston TX, US
Vaibhav Kapuria - Houston TX, US

Assignee:

The Board of Regents of the University of Texas System - Austin TX

International Classification:

A61K 31/538
C07D 213/46
A61K 31/44
C07C 255/44
A61K 31/275
C07D 233/64
A61K 31/4174
C07D 215/14
A61K 31/47
C07D 211/06
A61K 31/451
C07D 209/20
A61K 31/4045
C07D 333/24
A61K 31/381
C07D 265/36
A61P 35/00
A61P 19/02
A61P 9/10
A61P 17/06

US Classification:

5142305, 546330, 514357, 558401, 514521, 5483361, 514400, 546175, 514311, 546247, 514315, 548492, 514419, 549 69, 514438, 544105

Abstract:

The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. In general aspects, compounds of the present invention are tyrphostin-like in structure. Compounds of the present invention, in certain embodiments, display significant potency by causing, for example, inhibition of Stat3 activation, reduction in c-myc protein levels and/or induction of apoptosis in tumor cells. In general aspects, compounds of the present invention induce one or more of these activities at nanomolar concentrations and typically function through a unique mechanism involving the induction of stress granules that bind specific signaling molecules and prevent them from participating in signal transduction and oncogenesis.